EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-naïve HIV-hepatitis B co-infection

Fehmi Tabak iD, Dilek Yıldız Sevgi, Esra Zerdali, Ahmet Furkan Kurt, Hayat Kumbasar Karaosmanoğlu iD, Meliha Meriç Koç, Alper Gunduz, Ahsen Öncül, İnci Yilmaz Nakir, Esra Canpolat Ünlü iD, Ozlem Altuntaş Aydın, Bilgul Mete iD

International Journal of STD & AIDS · 2025

DOI: 10.1177/09564624251352345 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of STD & AIDS, 2025. Verfasst von Fehmi Tabak und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Adenine, Antiviral Agents, Coinfection, Hepatitis B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis B (HBV) infection affects 4%–14% of people with HIV infection in Turkey. Tenofovir alafenamide (TAF) is highly effective in treatment of HIV infection. While it is active against HBV, data on the use in HIV-HBV co-infection are limited. Patients and Methods We analyzed the efficacy of tenofovir disoproxil fumarate (TDF)- and TAF-containing regimens in patients with HIV-HBV co-infection from six centers in Istanbul, Turkey. The results of the cohort of 36 months were presented.

Results

259 patients were enrolled: 146 and 113 were receiving TAF- and TDF-containing regimens respectively. Baseline characteristics were comparable except TAF-containing group was older; had higher CD4 cell count and lower rate of CD4 count ≤200 cells/μL. Baseline HIV-RNA were 8.2 log copies/mL and 6.8 log in TAF- and TDF-containing groups, respectively ( p = .059) and HBV-DNA levels were 8.1 log IU/mL in both groups. Thirty-eight and 39% of the patients were HBeAg-positive. After 36 months, undetectable HBV-DNA was noted in 88% and 87%, and undetectable HIV-RNA in 85% and in 83% of TAF and TDF-containing groups, respectively. The increase in mean CD4 cell was significant in both groups: Δ = 311 cells/μL in TAF- and Δ = 393 cells/μL in TDF-containing groups. Rates of HBeAg loss (63% vs 57%), HBeAg seroconversion (35% vs 29%), HBsAg loss (29% vs 27%), and HBsAg seroconversion (23% vs 16%) were comparable at 36 months of therapy.

Conclusion

This real-life study showed that both TAF- and TDF-containing regimens are effective in co-infected patients. The rates of HBsAg loss seemed higher than those in HBV-monoinfected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAntiviral AgentsCoinfectionHepatitis BHIV InfectionsTenofovirAdultFemaleHumansMaleMiddle AgedAlanineAnti-HIV AgentsCD4 Lymphocyte CountDNA, ViralHepatitis B e AntigensHepatitis B virusHepatitis B, ChronicTreatment OutcomeTurkeyViral Load

Stichwörter der Autor:innen

Hepatitis B virusco-infectionhuman immunodeficiency virustenofovir alafenamidetenofovir disoproxil fumarate

Substanzen

AdenineAlanineAnti-HIV AgentsAntiviral AgentsDNA, ViralHepatitis B e AntigensTenofovirtenofovir alafenamide

Autor:innen und Institutionen

  • Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Department of Infectious Diseases and Clinical Microbiology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
  • Department of Infectious Diseases and Clinical Microbiology, Haseki Training and Research Hospital, Istanbul, Turkey.
  • Department of Infectious Diseases and Clinical Microbiology, Bakirköy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
  • Department of Infectious Diseases and Clinical Microbiology, Bezmi Alem Vakif University, Istanbul, Turkey.
  • Department of Infectious Diseases and Clinical Microbiology, Basaksehir Cam Sakura City Hospital, Istanbul, Turkey.

ORCID-Profile: Fehmi Tabak, Hayat Kumbasar Karaosmanoğlu, Esra Canpolat Ünlü, Bilgul Mete

Zitieren

APA

Tabak, F., Yıldız Sevgi, D., Zerdali, E., Kurt, A. F., Kumbasar Karaosmanoğlu, H., Meriç Koç, M., Gunduz, A., Öncül, A., Nakir, İ. Y., Canpolat Ünlü, E., Altuntaş Aydın, O., & Mete, B. (2025). Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-naïve HIV-hepatitis B co-infection. International Journal of STD & AIDS. https://doi.org/10.1177/09564624251352345

Vancouver

Tabak F, Yıldız Sevgi D, Zerdali E, Kurt AF, Kumbasar Karaosmanoğlu H, Meriç Koç M, et al. Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-naïve HIV-hepatitis B co-infection. International Journal of STD & AIDS. 2025. doi:10.1177/09564624251352345

BibTeX
@article{Tabak2025,
  author = {Tabak, Fehmi and Yıldız Sevgi, Dilek and Zerdali, Esra and Kurt, Ahmet Furkan and Kumbasar Karaosmanoğlu, Hayat and Meriç Koç, Meliha and Gunduz, Alper and Öncül, Ahsen and Nakir, İnci Yilmaz and Canpolat Ünlü, Esra and Altuntaş Aydın, Ozlem and Mete, Bilgul},
  title = {Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-naïve HIV-hepatitis B co-infection},
  journal = {International Journal of STD & AIDS},
  year = {2025},
  doi = {10.1177/09564624251352345}
}
Kostenlos starten →